XTLB Stock Analysis: Buy, Sell, or Hold?
XTLB - XTL Biopharmaceuticals Ltd. American Depositary Shares
$2.43
-0.02 (-0.82%)
▼
5d:
-7.6%
30d:
+199.63%
90d:
+318.97%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 29, 2026
25d
Get Alerted When XTLB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: XTLB is 25.9% above fair value ($1.93). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: XTLB is 25.9% above fair value ($1.93). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: XTLB is currently trading at $2.43, which is considered extended relative to its 30-day fair value range of $0.34 to $1.93.
Technical Outlook: Technically, XTLB is in a uptrend. Immediate support is located at $0.56, while resistance sits at $2.96.
Market Sentiment: XTLB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+1134.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XTLB is in a uptrend. Immediate support is located at $0.56, while resistance sits at $2.96.
Market Sentiment: XTLB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+1134.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.34 -
$1.93
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+25.9% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1134.6% below Wall St target ($30.00)
- WARNING: Recommendation downgraded due to 25.9% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.34 -
$1.93
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.56
Resistance Level
$2.96
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Wall Street Target
$30.00
(+1134.6%)
Earnings Growth (YoY)
-76.0%
Share & Embed Analysis
Last updated: April 02, 2026 7:10 PM ET
Data refreshes hourly during market hours. Next update: 8:10 PM
Data refreshes hourly during market hours. Next update: 8:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XTLB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |